View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 30, 2020

Fujifilm Biotech reserves manufacturing space for Gates Foundation’s Covid-19 accelerator

By Allie Nawrat

Fujifilm Diosynth Biotechnologies has agreed to reserve manufacturing capacity for a future Covid-19 therapy developed through the the COVID-19 Therapeutics Accelerator.

This programme was launched in March by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to remove barriers to drug development, and therefore speed up the therapeutic response to the novel coronavirus pandemic.

The manufacturing space reserved by Fujifilm Biotech in its facility in Hillerød, Denmark will be to support the supply of Covid-19 drugs to developing countries.

Fujifilm Biotech chief business officer Andy Fenny said: “Humanity is facing one of its most challenging times in recent history.

“Resolution calls for a global effort in collaboration between public, private and charitable entities.

“This partnership allows Fujifilm to deploy its leading technical expertise and significant production capacity to have a meaningful impact in the fight against this pandemic.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy